Form 4: Praxis Precision Medicines Director, Gregory Norden, Acquires Stock Options
SEC Form 4
Gregory Norden, a director at Praxis Precision Medicines, acquired stock options for 8,566 shares on June 5, 2024.
Summary
- On June 5, 2024, Gregory Norden, a director of Praxis Precision Medicines, Inc. [PRAX], acquired stock options for 8,566 shares.
- The exercise price of these options is $44.25.
- The options vest in twelve equal monthly installments starting on June 5, 2024, and expire on June 5, 2034.
- Following the transaction, Norden directly owns 8,566 derivative securities.
Sentiment
Score: 5
Explanation: This is a neutral event, simply a disclosure of stock option acquisition by a director.
Industry Context
Form 4 filings are standard disclosures required by the SEC when insiders, such as directors and officers, transact in their company's stock. This provides transparency to the market regarding insider activity.
Stakeholder Impact
- The acquisition of stock options by a director could be seen positively by shareholders as it aligns the director's interests with the company's performance.
Key Dates
| Date | Description |
|---|---|
| 06/05/2024 | Date of earliest transaction: Gregory Norden acquired stock options. |
| 06/05/2024 | Vesting start date for the stock options. |
| 06/05/2034 | Expiration date for the stock options. |
| 06/06/2024 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.